Diagnostics chain Metropolis Healthcare Ltd on Tuesday, May 13, reported a 19.4% year-on-year (YoY) dip in its Q4 net profit at ₹29 crore, down from ₹36 crore in Q4FY24.
Revenue from operations increased 4.3% to ₹345.3 crore against ₹331 crore last year.
EBITDA fell 22% YoY to ₹62.3 crore in the fourth quarter of this fiscal over ₹80 crore, while the EBITDA margin reduced to 18% over 24.2% in the year-ago quarter.
Also Read: Metropolis Healthcare CEO says Core Diagnostics acquisition may weigh on FY26 margins
In the full year FY25, Metropolis Healthcare reported a 6% YoY growth in patient volume and a 7% increase in test volume. Revenue per patient rose 6% YoY, driven by scientific upselling strategies and benefits from micro-market pricing.
The company’s B2C revenue saw robust growth of 17% for the full year and 14% in Q4FY25, supported by continued investments in improving consumer experience and expanding its service network. On the B2B front, revenue grew 12% YoY in FY25 and 10% in the fourth quarter, aided by improved service quality and stronger partner engagement.
TruHealth, the company’s wellness test portfolio, delivered a 24% growth in revenue in FY25, with Q4 revenue accounting for 19% of total revenues. Speciality diagnostics continued to maintain strong momentum with a 13% YoY growth during the year.
Also Read: Metropolis Healthcare to deepen North India footprint for the next growth phase
Revenue growth from tier-III cities contributed 18% to overall revenue in FY25. The company expanded its footprint to over 750 towns during the year, adding 29 new laboratories and 400 centres, significantly improving last-mile access.
The results came after the close of the market hours. Shares of Metropolis Healthcare Ltd ended at ₹1,702.10, down by ₹11.05, or 0.65%, on the BSE.
(Edited by : Shoma Bhattacharjee)
